Application | Comment | Organism |
---|---|---|
drug development | reduction of PI3K/PKCdelta activity represents a therapeutic target to downregulate adhesion molecule L1, CHL1, expression and thus benefit axonal regeneration after spinal cord injury | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
LY294002 | a PI3K antagonist | Mus musculus | |
PI3Kalpha inhibitor IV | - |
Mus musculus | |
PI3Kbeta inhibitor VI | i.e. TGX-221 | Mus musculus | |
PI3Kgamma inhibitor | - |
Mus musculus | |
Wortmannin | a PI3K antagonist | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
C57BL/6 mice | - |
Mus musculus C57BL/6 | - |
C57BL/6 mice | - |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
astrocyte | - |
Mus musculus | - |
brain | - |
Mus musculus | - |
cell culture | of astrocytes from cerebral cortices | Mus musculus | - |
Synonyms | Comment | Organism |
---|---|---|
PI3K | - |
Mus musculus |
PI3Kalpha | - |
Mus musculus |
PI3Kbeta | - |
Mus musculus |
PI3Kgamma | - |
Mus musculus |
General Information | Comment | Organism |
---|---|---|
malfunction | upregulation of expression of the close homologue of adhesion molecule L1, CHL1, by reactive astrocytes in the glial scar requires the activation of PI3K/PKCdelta-dependent pathways reduces axonal regeneration and inhibits functional recovery after spinal cord injury, overview | Mus musculus |
physiological function | PI3K is involved in LPS-induced signaling in glial cells inducing the lipopolysaccharide-stimulated expression of adhesion molecule L1, CHL1. PI3K/PKCdelta-mediated nuclear translocation of NF-kappaB | Mus musculus |